Chai Discovery

Building frontier AI to engineer better molecules

San Francisco, United States · Founded 2024 · $630.0M raised

Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$630.0M
Last Round
$400.0M Series CJul 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Chai Discovery is an AI drug discovery company that develops foundation models for molecular biology, enabling the prediction and design of biochemical interactions with atomic precision. The company's flagship model, Chai-1 and Chai-2, are multi-modal foundation models for predicting molecular structures and de novo antibody design. Chai-2 achieves an 85% success rate in zero-shot antibody discovery. Founded in 2024 by former OpenAI researchers, Chai has partnered with Eli Lilly for AI-driven biologics discovery and raised $130M in a Series B led by General Catalyst. The company operates as a partner-facing R&D and software organization supporting biologics discovery for biopharma customers.

Summary

Chai Discovery is an Artificial Intelligence company based in San Francisco, United States, founded in 2024. It has raised $630.0M in total across 4 rounds, most recently a $400.0M Series C round in Jul 2026. Investors include Index Ventures, Menlo Ventures and Kleiner Perkins.

Tech & App Stack

13 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CJul 2026
$400.0M

Sign up to see all 4 events

Funding: Seed through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Chai Discovery on Indexed.vc
<a href="https://indexed.vc/companies/chai-discovery"><img src="https://indexed.vc/api/badge/company/chai-discovery" alt="Chai Discovery on Indexed.vc" width="260" height="76" /></a>